Sophia Genetics Reaffirms FY23 Outlook: Revenue Growth At Or Above 30%, Operating Losses Below 2022 Levels
Portfolio Pulse from Benzinga Newsdesk
Sophia Genetics has reaffirmed its FY23 outlook, expecting full-year constant currency revenue growth excluding COVID-19-related revenue to be between 30% and 35%. The company also anticipates operating losses to be below 2022 levels.
August 08, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sophia Genetics' reaffirmed FY23 outlook of 30-35% revenue growth and lower operating losses could potentially boost investor confidence and positively impact the stock in the short term.
Sophia Genetics' reaffirmed FY23 outlook indicates strong revenue growth and improved operating efficiency, which are key indicators of a company's financial health. This could potentially boost investor confidence and positively impact the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100